A Registry for Patients Taking Uptravi

Using Electronic Medical Records, the change in Hemodynamics (by Right Heart Catherization), WHO FC and 6 Minute Walk Distance (by meters) from diagnosis to registry enrollment and to EOS will be measured/collected.

To describe demographics and disease characteristics of patients treated with Uptravi.

Time frame: Followed prospectively for a maximum of 18 months from the date of enrollment into the registry.

The initial dose (in micrograms), dose at selected intervals (in days), highest dose, maintenance dose, time between titrations, time from initiation to maintenance dose (in days) and total duration of exposure to Uptravi (in days) will be collected.

To describe the dosing regimens and titration of Uptravi, including any transition from other PAH specific therapies to Uptravi and from Uptravi to other prostanoids.

Time frame: Followed prospectively for a maximum of 18 months from the date of enrollment into the registry.

Occurrence of AEs and SAEs (incl. hospitalizations), discontinuation of Uptravi and reason for stopping and occurrence of all-cause death by relationship to PAH.

To describe the clinical course of patients treated with Uptravi.

Time frame: Followed prospectively for a maximum of 18 months from the date of enrollment into the registry.